Document Detail


On the evaluation of heparin and low molecular weight heparin in haemodialysis for chronic renal failure.
MedLine Citation:
PMID:  3744134     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Anticoagulation during haemodialysis for chronic renal failure can be assessed by measurement of plasma fibrinopeptide A (FPA) levels as an objective method of monitoring the initial step in fibrin formation, in conjunction with visual inspection of the dialyser circuit for fibrin clot deposition. Employing this approach, unfractionated commercial heparin administered as an intravenous bolus followed by an intravenous maintenance dose (5,000 IU + 1,500 IU/h) was found to suppress almost completely fibrin formation and deposition during prolonged dialysis. Comparison of a low molecular weight heparin, Kabi 2165, revealed that it can inhibit fibrin formation in the extracorporeal circulation, that this property is largely reflected in its anti-factor Xa activity in plasma, and that a useful and effective dose of Kabi 2165 for haemodialysis may be 4,000 anti-factor Xa U intravenous bolus + 750 anti-factor Xa U/h intravenous maintenance infusion. This dose only minimally alters the KCCT and corresponds to approximately 60% of that of unfractionated heparin, which may be important in the long-term use of heparin in these patients.
Authors:
D A Lane; A Flynn; H Ireland; E Anastassiades; J R Curtis
Related Documents :
2413564 - Metabolism of sodium pentosan polysulphate in man measured by a new competitive binding...
8807734 - Are the available low-molecular-weight heparin preparations the same?
8480784 - Pharmacy-managed, weight-based heparin protocol.
3022074 - Direct effects of heparin on basal and stimulated aldosterone production in rat adrenal...
2913864 - The effect of intravenously administered 2-chloroprocaine upon uterine artery blood flo...
14501784 - The impact of prenatal androgens on vaginal and urogenital sinus development in the fem...
Publication Detail:
Type:  Comparative Study; Journal Article    
Journal Detail:
Title:  Haemostasis     Volume:  16 Suppl 2     ISSN:  0301-0147     ISO Abbreviation:  Haemostasis     Publication Date:  1986  
Date Detail:
Created Date:  1986-10-16     Completed Date:  1986-10-16     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  0371574     Medline TA:  Haemostasis     Country:  SWITZERLAND    
Other Details:
Languages:  eng     Pagination:  38-47     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Biological Availability
Drug Administration Schedule
Evaluation Studies as Topic
Factor X / physiology
Factor Xa
Fibrinopeptide A / analysis
Heparin / administration & dosage,  blood,  pharmacology,  therapeutic use*
Humans
Injections, Intravenous
Injections, Subcutaneous
Kidney Failure, Chronic / drug therapy*,  therapy
Renal Dialysis*
Chemical
Reg. No./Substance:
25422-31-5/Fibrinopeptide A; 9001-29-0/Factor X; 9005-49-6/Heparin; EC 3.4.21.6/Factor Xa

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Intravenous and subcutaneous administration of Fragmin in deep venous thrombosis.
Next Document:  Pharmacokinetics of intravenously and subcutaneously administered Fragmin in healthy volunteers.